Atopy  ||| S:0 E:6 ||| NNP
as  ||| S:6 E:9 ||| IN
a  ||| S:9 E:11 ||| DT
risk  ||| S:11 E:16 ||| NN
factor  ||| S:16 E:23 ||| NN
for  ||| S:23 E:27 ||| IN
thyroid  ||| S:27 E:35 ||| JJ
autoimmunity  ||| S:35 E:48 ||| NN
in  ||| S:48 E:51 ||| IN
children  ||| S:51 E:60 ||| NNS
Recently ||| S:60 E:68 ||| RB
,  ||| S:68 E:70 ||| ,
there  ||| S:70 E:76 ||| EX
has  ||| S:76 E:80 ||| VBZ
been  ||| S:80 E:85 ||| VBN
considerable  ||| S:85 E:98 ||| JJ
interest  ||| S:98 E:107 ||| NN
in  ||| S:107 E:110 ||| IN
the  ||| S:110 E:114 ||| DT
relationship  ||| S:114 E:127 ||| NN
between  ||| S:127 E:135 ||| IN
allergic  ||| S:135 E:144 ||| NN
and  ||| S:144 E:148 ||| CC
autoimmune  ||| S:148 E:159 ||| JJ
diseases ||| S:159 E:167 ||| NNS
.  ||| S:167 E:169 ||| .
We  ||| S:169 E:172 ||| PRP
evaluated  ||| S:172 E:182 ||| VBD
the  ||| S:182 E:186 ||| DT
prevalence  ||| S:186 E:197 ||| NN
of  ||| S:197 E:200 ||| IN
thyroid  ||| S:200 E:208 ||| JJ
autoimmunity  ||| S:208 E:221 ||| NN
in  ||| S:221 E:224 ||| IN
566  ||| S:224 E:228 ||| CD
children  ||| S:228 E:237 ||| NNS
affected  ||| S:237 E:246 ||| VBN
by  ||| S:246 E:249 ||| IN
atopic  ||| S:249 E:256 ||| JJ
dermatitis  ||| S:256 E:267 ||| NNS
( ||| S:267 E:268 ||| -LRB-
AD ||| S:268 E:270 ||| NNP
) ||| S:270 E:271 ||| -RRB-
,  ||| S:271 E:273 ||| ,
urticaria ||| S:273 E:282 ||| NN
,  ||| S:282 E:284 ||| ,
rhinitis ||| S:284 E:292 ||| NN
,  ||| S:292 E:294 ||| ,
chronic  ||| S:294 E:302 ||| JJ
cough ||| S:302 E:307 ||| NN
,  ||| S:307 E:309 ||| ,
and  ||| S:309 E:313 ||| CC
asthma ||| S:313 E:319 ||| NN
.  ||| S:319 E:321 ||| .
Our  ||| S:321 E:325 ||| PRP$
results  ||| S:325 E:333 ||| NNS
suggest  ||| S:333 E:341 ||| VBP
that  ||| S:341 E:346 ||| DT
allergy  ||| S:346 E:354 ||| NN
and  ||| S:354 E:358 ||| CC
autoimmunity  ||| S:358 E:371 ||| NNS
can  ||| S:371 E:375 ||| MD
be  ||| S:375 E:378 ||| VB
two  ||| S:378 E:382 ||| CD
potential  ||| S:382 E:392 ||| JJ
outcomes  ||| S:392 E:401 ||| NNS
of  ||| S:401 E:404 ||| IN
dysregulated  ||| S:404 E:417 ||| JJ
immunity ||| S:417 E:425 ||| NN
.  ||| S:425 E:427 ||| .
It  ||| S:427 E:430 ||| PRP
is  ||| S:430 E:433 ||| VBZ
tempting  ||| S:433 E:442 ||| VBN
to  ||| S:442 E:445 ||| TO
speculate  ||| S:445 E:455 ||| VB
that  ||| S:455 E:460 ||| IN
NK  ||| S:460 E:463 ||| NNP
Th2  ||| S:463 E:467 ||| NNP
cells  ||| S:467 E:473 ||| NNS
can  ||| S:473 E:477 ||| MD
favour  ||| S:477 E:484 ||| VB
asthma  ||| S:484 E:491 ||| JJ
onset  ||| S:491 E:497 ||| NN
and  ||| S:497 E:501 ||| CC
at  ||| S:501 E:504 ||| IN
the  ||| S:504 E:508 ||| DT
same  ||| S:508 E:513 ||| JJ
time  ||| S:513 E:518 ||| NN
improve  ||| S:518 E:526 ||| VB
thyroid  ||| S:526 E:534 ||| JJ
autoimmunity ||| S:534 E:546 ||| NN
.  ||| S:546 E:548 ||| .
